Improving Clinical Trials in the Community Setting

Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies.

Russ Conroy

Darolutamide/ADT Safe, Effective for Black Men with Metastatic Prostate Cancer

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.

Benjamin Saylor

First-Line Adagrasib Shows Activity in STK11-Mutant KRAS G12C NSCLC

An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.

Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Ariana Pelosci

Higher AFM24 Exposure Boosts Response in Advanced NSCLC: AACR Data

A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.

Related Content

Sabrina Serani

May 2nd 2025

Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies.

Russ Conroy

Darolutamide/ADT Safe, Effective for Black Men with Metastatic Prostate Cancer

Benjamin Saylor

First-Line Adagrasib Shows Activity in STK11-Mutant KRAS G12C NSCLC

An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.

Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Ariana Pelosci